Table 2.

Clinical impact of IgG spike antibody titers and dose of tixagevimab-cilgavimab in patients with B-cell malignancies who received tixagevimab-cilgavimab

	SARS-CoV-2 negative	SARS-CoV-2 positive	P
IgG spike antibody titer beforetixagevimab-cilgavimab(AU/mL)	63	4	.1901
Median (range)	250 (14-800)	309 (41-643)
≥264, n (%)	12 (19)	2 (50)
<264, n (%)	51 (81)	2 (50)
IgG spike antibody titer after totixagevimab-cilgavimab(AU/mL)	25	4	>.999
Median (range)	800 (526-800)	681 (588-800)
≥264, n (%)	25 (100)	4 (100)
<264, n (%)	0 (0)	0 (0)
Tixagevimab-cilgavimab dose (mg), n (%)	224	27	.1804
150/150	11 (5)	3 (11)
300/300	213 (95)	24 (88)